02359 WUXI APPTEC
- 31.000
- -0.750-2.36%
WUXI APPTEC News
Wuxi AppTec (603259.SH) 2023 equity distribution: each share is distributed 0.98974 yuan.
Wuxi Apptec (603259.SH) released an announcement on the implementation of annual equity distribution in 2023: The current A shares will have a dividend of...
WuXi AppTec Goes Ex Dividend Tomorrow
Trending Industry Today: TIGERMED Leads Losses In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
June 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending lower today with 9 constituents down and TIGERMED leading Losses.$TIGERMED
Following a 37% Decline Over Last Year, Recent Gains May Please WuXi AppTec Co., Ltd. (SHSE:603259) Institutional Owners
Key Insights Institutions' substantial holdings in WuXi AppTec implies that they have significant influence over the company's share price A total of 25 investors have a majority stake in the compan
Wuxi Apptec will distribute a final dividend of 9.8974 yuan per 10 shares on July 5th.
Wuxi AppTec (02359) released an announcement that the company will distribute final dividends of RMB 9.8974 per 10 shares on July 5, 2024.
South Water continues to sell Moutai and invests nearly 500 million yuan in Luxshare Precision Industry, while North Water aggressively buys bank stocks.
Northward funds net sold A shares for 3.335 billion yuan, while southward funds net bought Hong Kong shares for 6.872 billion Hong Kong dollars.
Wuxi AppTec (02359) will distribute a final dividend of 9.8974 yuan per 10 shares on July 5th.
Wuxi Apptec (02359) announced that the company will distribute a final dividend of RMB per 10 shares on July 5, 2024.
WUXI APPTEC: (1) POLL RESULTS OF THE ANNUAL GENERAL MEETING OF 2023, THE 2024 SECOND A SHARE CLASS MEETING AND THE 2024 SECOND H SHARE CLASS MEETING; (2) PAYMENT OF CASH DIVIDEND; AND (3) AMENDMENTS TO ARTICLES OF ASSOCIATION
Infographic: Northbound capital net sold A shares by RMB 3.335 billion, and contra-traded by buying Luxshare Precision Industry and WuXi AppTec.
Northbound funds sold a net amount of 3.335 billion yuan of A-shares today, marking the third consecutive day of net selling. Among them, Kweichow Moutai, BYD Company Limited, and Shenzhen Inovance Technology experienced a net sell-off of 679 million yuan, 677 million yuan, and 256 million yuan, respectively. Luxshare Precision Industry and Wuxi AppTec received net purchases of 499 million yuan and 379 million yuan, respectively.
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
June 12th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(LIST1261.HK)$ is trending higher today with 8 constituents up and WUXI BIO leading Gains.$WUXI BIO(0
Wuxi Apptec (02359.HK) received a shareholding of 1,927,400 shares from JPMorgan.
According to the latest equity disclosure information from the Hong Kong Stock Exchange on June 6th, 2024, Wuxi Apptec (02359.HK) received an increase in shareholding of 1,927,400 shares from JPMorgan Chase & Co. at an average price of HKD 34.8647 per share, involving approximately HKD 67.1993 million. After the increase, the latest number of shares held by JPMorgan Chase & Co. is 35,525,040 shares, and the proportion of shares held increased from 8.67% to 9.17%.
Express News | JPMorgan Chase & Co's Long Position in H-Shares of WuXi AppTec Increases to 9.17% on May 30 From 8.67%- HKEX
Express News | Fitch Ratings Places Wuxi Apptec's 'bbb' Ratings on Rating Watch Negative
Fitch: Affected by the draft US Biosafety Law, Pharmacovigilance (2359.HK/603259.SH) BBB rating entered the watch list
On May 31, Fitch added the BBB rating and advanced unsecured rating of the long-term issuer of Kangde Pharmaceutical to the watch list. Fitch said the draft US Biosafety Act exposed Pharmacovigilance's credit status to potentially increased regulatory risks and uncertainties. It was also pointed out that the relevant plan is still in the process of legislative review and is subject to further review and revision. After the final provisions and implementation measures of the Biosafety Law were clarified, the Pharmacovigant Rating was removed from the watch list, and the impact of the aforementioned law on its credit was assessed. It is worth noting that among Fitch companies, the company that is currently closest to Kangde Pharmaceutical is Charles River (C)
Changes in Hong Kong stocks | CRO concept stocks picked up in early trading, and many companies began to adjust their business in the US. Institutions say industry demand is expected to recover in the second half of the year
CRO concept stocks picked up in early trading. As of press release, Viva Biotech (01873) rose 3.13% to HK$0.66; Kanglong Chemical (03759) rose 2.82% to HK$9.86; Pharmaceutical Biotech (02269) rose 2.68% to HK$11.5; and Pharmaceuticals (02359) rose 2.31% to HK$35.45.
WuXi AppTec Insider Lowered Holding By 15% During Last Year
From what we can see, insiders were net sellers in WuXi AppTec Co., Ltd.'s (SHSE:603259 ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it. Whil
Yao Ming Kangde plans to pay a cash dividend of 9.8,336 yuan for every 10 shares
Yao Ming Kangde (02359) announced that the company plans to distribute a cash dividend of RMB 9.8336 (tax included) for every 10 shares.
WuXi AppTec Adjusts Dividend After Share Changes
Yao Ming Kangde (02359) plans to distribute a cash dividend of 9.8336 yuan for every 10 shares
According to Zhitong Finance App, Yao Ming Kangde (02359) announced that the company plans to distribute a cash dividend of RMB 9.8336 (tax included) for every 10 shares.
WUXI APPTEC: ADJUSTMENT TO THE PER SHARE DISTRIBUTION AMOUNT OF THE CASH DIVIDEND UNDER THE 2023 PROFIT DISTRIBUTION PLAN
Analysis
Price Target
No Data
